Cadila Pharma Adds To Indian Biosimilars With Adalimumab
Plans To Continue Launching Biosimilars In Indian Market
After launching bevacizumab, rituximab and teriparatide biosimilars in the last two months, Cadila Pharma has added to the portfolio with the launch of Cadalimab (adalimumab) in India.
You may also be interested in...
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.